NASDAQ: ALPAlphaton Capital Corp Stock
$0.18-0.05 (-21.74%)
Updated Apr 23, 2026
ALP Price
$0.18
Fair Value Price
N/A
Market Cap
$1.05M
52 Week Low
$0.18
52 Week High
$13.80
P/E
-0.02x
P/B
0.11x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$14.89M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.26
Operating Cash Flow
-$4M
Beta
1.12
Next Earnings
Apr 28, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ALP Overview
Portage Biotech Inc. is a clinical-stage immuno-oncology company developing therapies to improve long-term treatment response and quality of life in patients with evasive cancers. The company's portfolio consists of five platforms leveraging delivery by (1) intratumorals, (2) nanoparticles, (3) liposomes, (4) aptamers, and (5) virus-like particles. Within these five platforms, the Company has 10 products under development. Portage Biotech was founded in 1973 and is headquartered in Tortola, British Virgin Islands.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ALP's potential to beat the market
- ALP doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Asset Management
Industry Rating
D
ALP
RankedUnranked of 78
RankedUnranked of 78
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $284.39 | B | |
| $56.47 | B | |
| $10.81 | B |
Be the first to know about important ALP news, forecast changes, insider trades & much more!
ALP News
Overview
Due Diligence Score
–
Industry Average (31)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ALP is good value based on its book value relative to its share price (0.11x), compared to the US Asset Management industry average (2.59x)
P/B vs Industry Valuation
ALP is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ALP due diligence checks available for Premium users.
Valuation
ALP fair value
Fair Value of ALP stock based on Discounted Cash Flow (DCF)
Price
$0.18
Fair Value
$1.41
Undervalued by
87.25%
ALP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ALP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.02x
Industry
32.29x
Market
31.09x
ALP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.11x
Industry
2.59x
ALP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ALP's financial health
Profit margin
Revenue
$0.0
Net Income
-$10.4M
Profit Margin
0%
ALP's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$30.6M
Liabilities
$21.7M
Debt to equity
2.26
ALP's short-term liabilities ($21.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALP's short-term assets ($19.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALP's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ALP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
ALP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALP vs Asset Management Stocks
Alphaton Capital Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.